Raid Aljumaily

3.1k total citations · 1 hit paper
81 papers, 1.3k citations indexed

About

Raid Aljumaily is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Raid Aljumaily has authored 81 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Oncology, 31 papers in Pulmonary and Respiratory Medicine and 17 papers in Molecular Biology. Recurrent topics in Raid Aljumaily's work include Cancer Immunotherapy and Biomarkers (38 papers), CAR-T cell therapy research (19 papers) and Lung Cancer Treatments and Mutations (13 papers). Raid Aljumaily is often cited by papers focused on Cancer Immunotherapy and Biomarkers (38 papers), CAR-T cell therapy research (19 papers) and Lung Cancer Treatments and Mutations (13 papers). Raid Aljumaily collaborates with scholars based in United States, Spain and Belgium. Raid Aljumaily's co-authors include Michael S. Gordon, Manish R. Patel, Jeffrey R. Infante, Andrea B. Apolo, Luc Dirix, Alain Ravaud, Patrick Schöffski, Manish Agrawal, John Ellerton and Ding Wang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Raid Aljumaily

76 papers receiving 1.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

2017 429 citations Manish R. Patel, John Ellerton et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Raid Aljumaily United States	15	1.0k	406	285	272	253	81	1.3k
Christoph Helwig Germany	18	1.2k 1.2×	218 0.5×	338 1.2×	465 1.7×	277 1.1×	53	1.4k
Boel Ragnarsson-Olding Sweden	20	1.1k 1.1×	240 0.6×	405 1.4×	326 1.2×	107 0.4×	30	1.4k
Darya Buehler United States	20	542 0.5×	186 0.5×	398 1.4×	145 0.5×	354 1.4×	69	1.4k
Lisa M. Cordes United States	20	1.2k 1.2×	266 0.7×	308 1.1×	522 1.9×	412 1.6×	105	1.6k
Julie E. Stein United States	12	658 0.6×	231 0.6×	211 0.7×	275 1.0×	281 1.1×	24	1.0k
Christopher A. Puleo United States	13	1.3k 1.3×	186 0.5×	325 1.1×	180 0.7×	112 0.4×	17	1.6k
Andrew S. Brohl United States	22	1.2k 1.2×	131 0.3×	426 1.5×	346 1.3×	528 2.1×	100	2.0k
Rodrigo Ramella Munhoz Brazil	14	822 0.8×	87 0.2×	309 1.1×	395 1.5×	281 1.1×	56	1.2k
Roberta Depenni Italy	18	679 0.7×	352 0.9×	270 0.9×	125 0.5×	306 1.2×	58	1.1k
Suroosh S. Marzban United States	19	921 0.9×	63 0.2×	235 0.8×	229 0.8×	175 0.7×	25	1.1k

Countries citing papers authored by Raid Aljumaily

Since Specialization

Citations

This map shows the geographic impact of Raid Aljumaily's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raid Aljumaily with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raid Aljumaily more than expected).

Fields of papers citing papers by Raid Aljumaily

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raid Aljumaily. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raid Aljumaily. The network helps show where Raid Aljumaily may publish in the future.

Co-authorship network of co-authors of Raid Aljumaily

This figure shows the co-authorship network connecting the top 25 collaborators of Raid Aljumaily. A scholar is included among the top collaborators of Raid Aljumaily based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raid Aljumaily. Raid Aljumaily is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chae, Young Kwang, Megan Othus, Sandip Pravin Patel, et al.. (2025). A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort. Cancer Communications. 45(8). 976–986.

Sen, Triparna, Virginia Corbett, Sonam Puri, et al.. (2025). Pulmonary neuroendocrine neoplasms: the molecular landscape, therapeutic challenges, and diagnosis and management strategies. The Lancet Oncology. 26(1). e13–e33. 8 indexed citations

Fontana, Emily, Meredith McKean, Raid Aljumaily, et al.. (2024). 647P EphA2-targeting bicycle toxin conjugate (BTC) BT5528 in patients (pts) with advanced solid tumors: A phase I/II study. Annals of Oncology. 35. S511–S512.

Heumann, Thatcher, Michael Cecchini, Raid Aljumaily, et al.. (2024). A phase I study of irinotecan combined with BAY1895344 (ATR inhibitor) in advanced solid tumors: Results of ETCTN 10402 dose escalation.. Journal of Clinical Oncology. 42(16_suppl). 3077–3077. 1 indexed citations

Perez, Bradford A., Raid Aljumaily, Thomas U. Marron, et al.. (2024). Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors. ESMO Open. 9(2). 102217–102217. 10 indexed citations

Abrams, Ross A., Kathryn Winter, Karyn A. Goodman, et al.. (2024). NRG Oncology/RTOG 0848: Results after adjuvant chemotherapy +/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA).. Journal of Clinical Oncology. 42(16_suppl). 4005–4005. 9 indexed citations

Tchelebi, Leila T., Kathryn Winter, Ross A. Abrams, et al.. (2023). Analysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848. International Journal of Radiation Oncology*Biology*Physics. 118(1). 107–114. 6 indexed citations

Schweizer, Michael T., Atish D. Choudhury, Vadim Doronin, et al.. (2022). 488P Phase I trial of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in follicular lymphoma (FL), small cell lung cancer (SCLC) and castration-resistant prostate cancer (CRPC). Annals of Oncology. 33. S763–S764. 4 indexed citations

Tchelebi, Leila T., Kathryn Winter, Ross A. Abrams, et al.. (2021). Analysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848. International Journal of Radiation Oncology*Biology*Physics. 111(3). S40–S40. 3 indexed citations

10.

Moreno, Víctor, Pilar Garrido, Kyriakos P. Papadopoulos, et al.. (2021). Tolerability and antitumor activity of cemiplimab, a human monoclonal anti–PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort. Lung Cancer. 155. 151–155. 11 indexed citations

11.

Moore, Kathleen N., David S. Hong, Manish R. Patel, et al.. (2021). A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer. Targeted Oncology. 16(5). 569–589. 20 indexed citations

12.

Balmanoukian, Ani Sarkis, Jeffrey R. Infante, Raid Aljumaily, et al.. (2020). Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors. Clinical Cancer Research. 26(23). 6196–6203. 40 indexed citations

13.

Morgensztern, Daniel, Chao Huang, Christian Rolfo, et al.. (2020). A phase III trial-in-progress called REPLATINUM that compares RRx-001 + a platinum doublet to a platinum doublet in third-line or beyond small cell lung cancer.. Journal of Clinical Oncology. 38(15_suppl). TPS9083–TPS9083. 2 indexed citations

14.

Jimeno, Antonio, Kathleen N. Moore, Michael S. Gordon, et al.. (2018). A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. Investigational New Drugs. 37(3). 461–472. 61 indexed citations

15.

Moreno, Víctor, Emiliano Calvo, Marta Gil-Martín, et al.. (2018). Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, in patients with non-small cell lung cancer (NSCLC): Interim data from phase 1 dose escalation and NSCLC Expansion Cohort.. Journal of Clinical Oncology. 36(15_suppl). e21057–e21057. 3 indexed citations

16.

Hecht, J. Randolph, Aung Naing, Gerald S. Falchook, et al.. (2017). Overall survival and immunologic responses in metastatic pancreatic adenocarcinoma (PDAC) on PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX). Annals of Oncology. 28. v254–v254. 1 indexed citations

17.

Apolo, Andrea B., John Ellerton, Jeffrey R. Infante, et al.. (2017). Avelumab treatment of metastatic urothelial carcinoma (mUC) in the phase 1b JAVELIN solid Tumor study: updated analysis with ≥6 months of follow-up in all patients. Annals of Oncology. 28. v300–v301. 17 indexed citations

18.

Patel, Manish R., John Ellerton, Jeffrey R. Infante, et al.. (2017). Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. The Lancet Oncology. 19(1). 51–64. 429 indexed citations breakdown →

19.

Aljumaily, Raid, et al.. (2014). Oligometastatic non-small cell lung cancer treated with curative intent.. Journal of Clinical Oncology. 32(15_suppl). e19034–e19034. 1 indexed citations

20.

Kaimal, Rajani, Raid Aljumaily, Sarah L. Tressel, et al.. (2013). Selective Blockade of Matrix Metalloprotease-14 with a Monoclonal Antibody Abrogates Invasion, Angiogenesis, and Tumor Growth in Ovarian Cancer. Cancer Research. 73(8). 2457–2467. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact